Author

Y. Y. Chen

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Research Focus:cell type annotation· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

A. Alag· 1 shared A. Lakhani· 1 shared A. Marson· 1 shared A. Shafer· 1 shared A. To· 1 shared B. Y. Ji· 1 shared C. E. Brown· 1 shared C. J. Ye· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Alag

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Modular Pooled Discovery of Synthetic Knockin Sequences to Program Durable Cell Therapies

F. Blaeschke, Y. Y. Chen, R. Apathy, Z. Li, C. T. Mowery, W. A. Nyberg, A. To, R. Yu, R. Bueno, M. C. Kim, R. Schmidt, D. B. Goodman, T. Feuchtinger, J. Eyquem, C. J. Ye, , A. Marson

The paper develops ModPoKI, a platform for modular construction of DNA knockin libraries to identify gene constructs that enhance T cell function and persistence.

bioRxiv · Jul 27, 2022Immunology

Rational Tuning of CAR Tonic Signaling Yields Superior T-Cell Therapy for Cancer

X. Chen, M. Khericha, A. Lakhani, X. Meng, E. Salvestrini, L. C. Chen, A. Shafer, A. Alag, Y. Ding, D. Nicolaou, J. O. Park, Y. Y. Chen

This study shows that tuning CAR tonic signaling improves T-cell therapy efficacy by designing CARs with low but non-zero tonic signaling, enhancing anti-tumor activity in mouse models.

bioRxiv · Oct 1, 2020 · PreprintBioengineering

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma

E. Zah, E. Nam, V. Bhuvan, V. T. T. Tran, B. Y. Ji, S. B. Gosliner, X. Wang, C. E. Brown, Y. Y. Chen

This study develops BCMA/CS1 bispecific CAR-T cells that effectively target heterogeneous multiple myeloma, showing improved activity and durable tumor-free survival compared to single-target CAR-T cells.

bioRxiv · Mar 12, 2020Bioengineering